CEO Kapusta Sells Shares for Tax Purposes, UniQure Stock Volatility Rises—Investors Urged to Watch Regulatory Milestones

Insider Selling Signals at uniQure NV

The latest filing on March 2, 2026 shows CEO Matthew Kapusta selling 34,437 ordinary shares at a weighted average of $9.95. The sale was triggered by restricted‑share‑unit vesting and intended solely to cover withholding taxes—an automatic, non‑discretionary transaction. While the price is roughly 30 % above the market close of $7.88, the deal does not indicate a loss of confidence; rather, it reflects routine tax planning. Nonetheless, the timing—just days after a wave of executive sales—has amplified market chatter. Social‑media buzz hit 253 % and sentiment skews positive (+2), suggesting that investors view the move as a normal tax‑related liquidation rather than a signal of impending decline.

What the Pattern Means for Investors

Across the board, senior executives in March sold roughly 23,600 shares each, all at $9.95, while their post‑trade holdings remained substantial (KLEMT Christians at 198 981 shares, POTTS Jeannette at 106 495, ABIS‑SAAB at 148 777). These sales coincide with a steep decline in the stock’s weekly (-55 %) and monthly (-53 %) performance, and an ongoing regulatory drag on the company’s flagship Huntington’s disease program. For investors, the pattern suggests that insiders are monetising tax‑related gains rather than taking a bearish stance. However, the cumulative effect of multiple sell orders could exacerbate downward pressure if market sentiment turns negative, especially given the current analyst downgrades and the lack of a clear near‑term revenue driver.

Kapusta’s Historical Trading Profile

Kapusta’s earlier transaction on February 25, 2026 involved a 12,378‑share sale at $23.86, cutting his holdings to 639,076 shares. Compared with the March sale, the price was higher but the volume was lower, consistent with a partial tax‑coverage strategy. Historically, the CEO has sold shares in bulk only when restricted units vest or during significant corporate events. His post‑transaction holdings typically remain above 600,000 shares—well over 10 % of the public float—indicating a long‑term commitment. The March sale, therefore, does not represent a shift in ownership philosophy but rather a routine tax‑management step.

Implications for UniQure’s Future

UniQure’s valuation has tightened under analyst scrutiny, with key banks downgrading the stock amid regulatory uncertainties. The recent insider sales, while non‑discretionary, add a layer of market volatility during a period of already subdued investor confidence. If the company can deliver positive Phase III data for AMT‑130 and secure a timely U.S. launch, insider confidence may rebound, potentially curbing the sell pressure. Until then, investors should monitor both the insider activity and the company’s regulatory milestones, as these will be the primary drivers of the stock’s near‑term trajectory.